BACKGROUND AND OBJECTIVES: We sought to study the impact of neoadjuvant therapy (NAT) on @entity260 following surgical resection of @entity420 of the stomach and gastroesophageal junction (GEJ). METHODS: We compared the postoperative outcomes of 308 @entity1 undergoing a surgery-first approach and 145 @entity1 undergoing NAT followed by curative-intent surgery for @entity420 of the stomach and GEJ from 1995-2014. RESULTS: @entity1 receiving NAT were more likely to be younger, have @entity5 of the GEJ, to undergo esophagogastrectomy and D2 lymphadenectomy, and to have more advanced stage disease than @entity1 undergoing surgery first. There were no differences in overall 30-day morbidity or mortality rates between the groups, yet @entity1 undergoing surgery first were more likely to have higher-grade complications than those undergoing NAT. Age >65 years, higher ASA score, concomitant splenectomy, more @entity5 stage, and year of surgery were independent risk factors for postoperative morbidity, but receipt of NAT was not an independent predictor of postoperative morbidity. CONCLUSIONS: Despite having more advanced disease and undergoing higher-risk surgical procedures, @entity1 with @entity420 of the stomach or GEJ who receive NAT prior to surgery are no more likely to @entity260 than @entity1 treated with a surgery-first approach. J. Surg. Oncol. 2016;113:560-564.    2016 Wiley Periodicals, Inc.

The impact of neoadjuvant therapy for gastroesophageal XXXX on postoperative morbidity and mortality.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['advanced tumor', 'tumors'] @entity260 :: ('MESH:D011183', 'Disease') :: ['suffer postoperative complications', 'postoperative complications']
@entity420 :: (MESH:D000230,Disease) :: ['adenocarcinoma']
